151 related articles for article (PubMed ID: 38157276)
1. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy.
Wei L; Li Z; Guo S; Ma H; Shi Y; An X; Huang K; Xiong L; Xue T; Zhang Z; Yao K; Luo J; Han H
Cancer; 2024 May; 130(9):1650-1662. PubMed ID: 38157276
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
3. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma.
Bandini M; Ross JS; Zhu Y; Ye DW; Ornellas AA; Watkin N; Ayres BA; Hakenberg OW; Heidenreich A; Salvioni R; Catanzaro M; Raggi D; Giannatempo P; Marandino L; Haidl F; Pederzoli F; Briganti A; Montorsi F; Chipollini J; Azizi M; De Meerleer G; Brouwer OR; Grass GD; Johnstone PA; Albersen M; Spiess PE; Necchi A
Eur Urol Oncol; 2021 Oct; 4(5):802-810. PubMed ID: 33199252
[TBL] [Abstract][Full Text] [Related]
4. Immune landscape and immunotherapy for penile cancer.
Tang Y; Hu X; Wu K; Li X
Front Immunol; 2022; 13():1055235. PubMed ID: 36524123
[TBL] [Abstract][Full Text] [Related]
5. The effects of HIV and oncogenic human papillomavirus on the tumor immune microenvironment of penile squamous cell carcinoma.
Mumba C; Muhimbe Z; Mapulanga V; Kawimbe M; Mutale K; Hamasuku A; Musumali J; Mwale NK; Ngalamika O
PLoS One; 2024; 19(5):e0300729. PubMed ID: 38691575
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Pond GR; Di Lorenzo G; Necchi A; Eigl BJ; Kolinsky MP; Chacko RT; Dorff TB; Harshman LC; Milowsky MI; Lee RJ; Galsky MD; Federico P; Bolger G; DeShazo M; Mehta A; Goyal J; Sonpavde G
Urol Oncol; 2014 May; 32(4):501-8. PubMed ID: 24332646
[TBL] [Abstract][Full Text] [Related]
7. Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis.
Ferrándiz-Pulido C; Masferrer E; de Torres I; Lloveras B; Hernandez-Losa J; Mojal S; Salvador C; Morote J; Ramon y Cajal S; Pujol RM; Garcia-Patos V; Toll A
J Am Acad Dermatol; 2013 Jan; 68(1):73-82. PubMed ID: 22863066
[TBL] [Abstract][Full Text] [Related]
8. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer.
Yan R; Ma H; Jiang L; Guo S; Shi Y; Sheng X; Zhang Y; Spiess PE; Liu T; Xue T; Chen X; Li Z; An X; Yao K; Zhou F; Han H
BJU Int; 2023 Feb; 131(2):198-207. PubMed ID: 35704436
[TBL] [Abstract][Full Text] [Related]
9. Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.
Azizi M; Tang DH; Verduzco D; Peyton CC; Chipollini J; Yuan Z; Schaible BJ; Zhou JM; Johnstone PA; Giuliano A; Dhillon J; Spiess PE
Clin Genitourin Cancer; 2019 Feb; 17(1):e80-e91. PubMed ID: 30318447
[TBL] [Abstract][Full Text] [Related]
10. National trends and survival outcomes of penile squamous cell carcinoma based on human papillomavirus status.
Chipollini J; Pollock G; Hsu CH; Batai K; Recio-Boiles A; Lee BR
Cancer Med; 2021 Nov; 10(21):7466-7474. PubMed ID: 34632731
[TBL] [Abstract][Full Text] [Related]
11. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization.
Elst L; Philips G; Vandermaesen K; Bassez A; Lodi F; Vreeburg MTA; Brouwer OR; Schepers R; Van Brussel T; Mohanty SK; Parwani AV; Spans L; Vanden Bempt I; Jacomen G; Baldewijns M; Lambrechts D; Albersen M
Eur Urol; 2024 Apr; ():. PubMed ID: 38670879
[TBL] [Abstract][Full Text] [Related]
12. The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.
Steinestel J; Al Ghazal A; Arndt A; Schnoeller TJ; Schrader AJ; Moeller P; Steinestel K
BMC Cancer; 2015 Apr; 15():220. PubMed ID: 25885064
[TBL] [Abstract][Full Text] [Related]
13. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases.
Hrudka J; Hojný J; Prouzová Z; Kendall Bártů M; Čapka D; Zavillová N; Matěj R; Waldauf P
Pathology; 2024 Apr; 56(3):357-366. PubMed ID: 38161143
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
16. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study.
García Del Muro X; Páez López-Bravo D; Cuéllar-Rivas MA; Maroto P; Giannatempo P; Castellano D; Climent MA; P Valderrama B; Gómez de Liaño A; López-Montero L; Mina L; Alcalá-López D; Sampayo-Cordero M; Necchi A
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38749903
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
18. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
20. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
